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Abstract
Canine glaucoma is a group of disorders that are generally associated with increased 
intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma 
is a leading cause of irreversible vision loss in dogs and may be either primary or 
secondary. Despite the growing spectrum of medical and surgical therapies, there 
is no cure, and many affected dogs go blind. Often eyes are enucleated because of 
painfully high, uncontrollable IOP. While progressive vision loss due to primary 
glaucoma is considered preventable in some humans, this is mostly not true for dogs. 
There is an urgent need for more effective, affordable treatment options. Because 
newly developed glaucoma medications are emerging at a very slow rate and may 
not be effective in dogs, work toward improving surgical options may be the most 
rewarding approach in the near term. This Viewpoint Article summarizes the discus-
sions and recommended research strategies of both a Think Tank and a Consortium 
focused on the development of more effective therapies for canine glaucoma; both 
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1 |  INTRODUCTION
Canine glaucoma is an often painful, complex group of 
blinding optic neuropathies that have in common elevated in-
traocular pressure (IOP) leading to loss of retinal ganglion cells 
(RGCs) and their axons, associated with degeneration of optic 
nerve head (ONH) and retina. Glaucoma is a leading cause of 
irreversible vision loss in both humans and dogs.1-4 Impaired 
aqueous humor drainage through the physiologic outflow 
pathways is responsible for increases in IOP. Canine glaucoma 
is defined as either primary or secondary, the latter being 
caused by a clinically or histopathologically detectable under-
lying disease process. Secondary glaucoma is among the most 
feared complications following canine cataract surgery with 
an estimated incidence of 5%‐19% over a 2‐year postoperative 
period; in some breeds, such as Boston Terriers, Shih Tzus, 
and Labrador Retrievers, this glaucoma incidence can rise to 
29%‐38%, suggesting a possible hereditary component.5-11 
Current medical and surgical treatments aim at slowing vision 
loss by maintaining IOP at a healthy level. The range of such 
a nondamaging IOP is poorly understood and likely varies be-
tween individuals based on factors such as the biomechanical 
properties of the eye. For many forms of canine glaucoma, 
there is no cure with vision loss progressing despite intensive 
and costly medical and surgical treatments. This is in contrast 
to primary glaucoma in human patients where vision loss is 
manageable and can be prevented in some with early diagnosis 
and intervention.12 Glaucoma therapies in dogs frequently fail 
within months with rebounding IOP elevation and blindness, 
thus illustrating a need for more effective, affordable treatment 
options. During a recent survey performed by the American 
College of Veterinary Ophthalmologists Vision for Animals 
Foundation (ACVO‐VAF), a majority of responding ACVO 
Diplomates (board certified veterinary ophthalmologists) 
consider research toward this goal one of the most pressing 
needs based on their clinical practice. Because newly devel-
oped glaucoma medications are emerging at a very slow rate, 
are optimized for the human eye, and may not show enhanced 
efficacy in dogs, the survey revealed that focus on improved 
surgical therapies may be the most rewarding approach in the 
near term.
On November 5, 2016, the ACVO‐VAF organized and 
funded its second Think Tank at the Detroit Metropolitan 
Airport Westin Hotel in Michigan (USA) to develop recom-
mendations for research and clinical strategies toward im-
provement of canine glaucoma therapies, with a special focus 
on surgical treatments. The event was followed by the estab-
lishment of a Canine Glaucoma Consortium to (a) review and 
update nomenclature, (b) create toolkits for data collection, 
(c) coordinate research efforts, (d) review and compile clini-
cal and research data and samples, (e) establish more accurate 
glaucoma classifications, and (f) review emerging discover-
ies. This Viewpoint Article summarizes the discussions and 
recommended strategies of both Think Tank and Consortium; 
they are grouped under the following main topics: (a) Better 
understanding of disease mechanisms, (b) early glaucoma di-
agnosis and disease staging, (c) optimization of IOP‐lowering 
medical treatment, (d) new surgical therapies to control IOP, 
and (e) novel treatment strategies, such as gene and stem cell 
therapies, neuroprotection, and neuroregeneration. Potential 
differences in depth of focus between these topics correlate 
with how they were weighed during our deliberations.
2 |  BETTER UNDERSTANDING OF 
DISEASE MECHANISMS
Despite recent experimental advances in the protection and 
regeneration of RGCs and their axons, lowering IOP to pre-
vent or slow ONH damage will remain the main focus of 
canine glaucoma therapy in the foreseeable future. In order 
to develop more effective treatments that target specific dis-
ease mechanisms, it is critical that the anatomy and physiol-
ogy of aqueous humor outflow pathways are evaluated in 
greater detail in normal and glaucomatous eyes (Figure 1). 
Frequently, assumptions are made that these pathways in 
dogs are similar to human eyes; however, this is not true in 
all aspects. For example, the pectinate ligament, dysplasia of 
were organized and funded by the American College of Veterinary Ophthalmologists 
Vision for Animals Foundation (ACVO‐VAF). The recommendations consist of (a) 
better understanding of disease mechanisms, (b) early glaucoma diagnosis and dis-
ease staging, (c) optimization of IOP‐lowering medical treatment, (d) new surgical 
therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell 
therapies, neuroprotection, and neuroregeneration. In order to address these needs, 
increases in research funding specifically focused on canine glaucoma are necessary.
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which is considered a risk factor for the development of ca-
nine primary angle‐closure glaucoma (PACG), is present in 
dogs but not humans. Another example is the differences in 
the post‐trabecular meshwork outflow pathways, including 
human Schlemm's canal vs canine angular aqueous plexus. 
While the human Schlemm's canal has been studied in de-
tail, much remains to be learned about the canine angular 
aqueous plexus and its role in glaucoma pathogenesis. We 
also need to improve our knowledge of canine glaucoma risk 
factors and pathogenesis, including differences between the 
dog and other species and between individual canine breeds, 
to allow earlier diagnosis and treatment to prevent continued 
RGC loss and blindness. We believe that early disease rec-
ognition will be facilitated by the increased accessibility and 
affordability of powerful diagnostic technologies, includ-
ing high‐resolution imaging tools (eg, high‐resolution ul-
trasonography [HRUS]/ultrasound biomicroscopy [UBM], 
optical coherence tomography [OCT], and anterior seg-
ment angiography) and more frequent IOP measurements 
by telemetric devices or home monitoring. Furthermore, as 
shown by recent advances in canine glaucoma genetics, im-
proving molecular laboratory tools, such as next‐generation 
sequencing and proteomics, facilitate the detailed investiga-
tion of genetic risk factors as well as molecular and cellular 
disease mechanisms. Table 1 lists specific topics related to 
canine primary and secondary glaucoma that we identified 
as important. The list represents our discussions in that it fo-
cuses on the anterior segment and IOP. We avoided further 
prioritization because choice of research topic and wording 
of specific aims will depend on the expertise and resources 
available to an individual investigator or team. While 
multiple forms of secondary glaucoma exist, our discussions 
focused on postphacoemulsification glaucoma.
3 |  EARLY GLAUCOMA 
DIAGNOSIS AND DISEASE STAGING
Closely associated with the incomplete understanding of dis-
ease mechanisms is our inability to diagnose preclinical dis-
ease stages and to predict disease onset, especially in canine 
PACG. Addressing this shortcoming is critical to determine 
when more effective treatment should be initiated to delay or 
prevent vision loss (Table 2). This challenge may be addressed 
by novel and/or improving diagnostic technologies that will 
allow a more detailed structural and functional assessment of 
the eye and for an evaluation of the effect of various glaucoma 
drugs on the outflow pathways in glaucoma.13,14 Many of these 
technologies are being developed in a laboratory setting and/
or for application in human patients, and they need to be vali-
dated for dogs. It is beyond the scope of this article to list pros 
and cons for all of these methods, but continual assessment of 
their usefulness is needed since they are constantly evolving. 
Technological advances have been most dramatic in high‐reso-
lution imaging, such as OCT and HRUS/UBM (Figures 2 and 
3), and functional testing such as chromatic pupillary light re-
flex and advanced electroretinography.15-20 As prices for many 
of these technologies decrease, and they become more user‐
friendly, their application will be more realistic for the veteri-
nary practice. To go even further, improvements of monitoring 
by dog owners will likely become possible in the not too distant 
future thanks to smartphone applications, user‐friendly home 
tonometry, and continuous IOP monitoring with telemetric 
F I G U R E  1  Cross‐sectional anatomy (A) and aqueous humor drainage routes (B) in the canine eye. Once through the trabecular meshwork, 
the aqueous can pass into the angular aqueous plexus and is directed either anteriorly into the more superficial episcleral venules (1) or posteriorly 
into the scleral venous plexus and the vortex venous system (2). An alternative aqueous humor drainage pathway (3) is the diffusion through 
the ciliary muscle interstitium to the suprachoroidal space and through the sclera (ie, uveoscleral flow). Abbreviation: AVAs, arteriovenous 
anastomosis (from Tsai et al14; with permission)
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technologies.21,22 The development of tools to recognize and 
identify a healthy IOP range with its individual variability will 
be important for early diagnosis. Progress in canine glaucoma 
genetics has been made, especially for primary open‐angle 
glaucoma (POAG), but more work needs to be done to identify 
reliable disease markers that help in risk assessment and diag-
nosis, especially for canine PACG, which is more challenging 
to investigate because of its complex nature.23,24 The ACVO‐
VAF Canine Glaucoma Consortium is initiating and coordinat-
ing a large‐scale, multicenter project to collect DNA and tissue 
samples, and gonioscopy and UBM iridocorneal angle meas-
urements from glaucoma‐affected and control dogs to develop 
improved biomarkers that allow reliable identification of early, 
preclinical glaucoma stages and/or dogs at risk of developing 
disease. For example, the development of a chip‐based diag-
nostic DNA test may facilitate the early detection and treat-
ment of hereditary glaucoma based on the presence of specific 
genetic markers years before the emergence of clinical signs. 
T A B L E  1  High‐priority research topics toward the better 
understanding of canine glaucoma disease mechanisms
Canine ocular anatomy and physiology 
Characterization of:
‐ Anterior chamber anatomy and dimensions.
‐ Aqueous humor dynamics, including estimation of conventional 
and unconventional outflow, by measurement of episcleral 
venous pressure, tonography, and fluorophotometry.
‐ Aqueous humor outflow pathway structure and function.
‐ Effect of gender, breed, and age on anatomy and physiology 
of the anterior segment, including aqueous humor outflow 
pathways.
Pathogenesis of elevated IOP in canine breed‐specific, primary 
glaucoma 
Description of (including potential age‐effect):
‐ Genetic risk factors.
‐ Role of anterior chamber depth.
‐ Location of increased outflow resistance, including segmental 
variations.
‐ Role of pectinate ligament and pectinate ligament dysplasia and 
its relationship with ciliary cleft width.
‐ Width of ciliary cleft at different disease stages and forms of 
disease, including segmental variations.
‐ Role of iris volume, shape (“plateau iris”), and pupillary block in 
iridocorneal angle closure.
‐ Effect of lens, including size and position, and lens zonules on 
aqueous humor outflow pathways, especially ciliary cleft.
‐ Role of episcleral venous pressure.
‐ Role of uveoscleral outflow.
‐ Role of inflammation.
‐ Role of pigment dispersion.
‐ Altered scleral biomechanics (stiffness) on aqueous humor out-
flow, including width of ciliary cleft and posterior uveoscleral 
outflow.
‐ Role of angular aqueous plexus.
‐ Role of choroidal thickness changes, including pulsatile 
component.
‐ Pathogenesis of canine optic nerve head and retinal degeneration
‐ Investigation of:
‐ Pathogenesis of tapetal sparing (less retinal atrophy superior vs. 
inferior).
‐ Role of abnormal ocular perfusion.
Pathogenesis of postphacoemulsification glaucoma 
Improve our understanding of:
‐ Risk factors and differences to other species, including human.
‐ Role of inflammation and use of anti‐inflammatory drugs
‐ Effect of globe size.
‐ Effect of pectinate ligament dysplasia.
‐ Changes in ciliary cleft and lens zonule tension following cata-
ract surgery.
‐ Role of surgeon experience.
‐ Possible correlation with postoperative hypertension.
‐ Effect of intraocular lens and capsular tension ring on ciliary 
cleft width and glaucoma development.
‐ Factors contributing to pre‐iridal fibrovascular membrane 
(PIFVM) formation and its role in secondary glaucoma 
development.
T A B L E  2  Potential strategies toward improved early diagnosis, 
staging, and response to therapy of canine glaucoma
Detailed clinical and genetic definition of breed‐specific forms of 
primary glaucoma with similarities and differences with human 
forms of glaucoma.
Development of more accurate classification of canine glaucoma.
Standardization and development of grading scheme for ultrasound 
biomicroscopy measurements and ciliary cleft width.
Facilitation of routine direct and indirect measurement of aqueous 
humor dynamics, such as episcleral venous pressure, tonography, 
and fluorophotometry, allowing estimation of conventional and 
unconventional outflow.
Development of continuous tonometry and determination of its 
value for early diagnosis.* 
Definition of safe, healthy target IOP, and its potential individual 
variability.
Routine assessment of iridocorneal angle morphology and regional 
variability, including pectinate ligament dysplasia and width of 
ciliary cleft.
Review and revision of relevant and definable iridocorneal angle 
classification, including the effect of age and disease.
Validation and comparison of high‐resolution imaging technolo-
gies, for both anterior and posterior segment.* 
Development of functional techniques, such as electroretinography 
and pupillometry, for early detection of retinal and optic nerve 
damage.* 
Development of molecular and genetic glaucoma markers for clini-
cal application.
Determination of inter‐individual differences in responsiveness to 
glaucoma drugs and nonresponder rates.
*Many of these technologies already exist but need to be validated for canine 
glaucoma. 
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Early therapeutic intervention could result in significant delay 
or prevention of advanced disease and vision loss.
4 |  OPTIMIZATION OF IOP‐
LOWERING MEDICAL TREATMENT
Medical therapies continue to play an important role either 
separately or concurrent with surgical treatments. To date, 
the only treatable glaucoma risk factor is IOP; additional 
medical treatment options may be identified in the future. 
Current drugs are aimed at either decreasing aqueous humor 
production or improving drainage through conventional and 
unconventional pathways (Figure 1). Unfortunately, the de-
velopment of new, IOP‐lowering medications has been slow 
and most of these medications are optimized to treat human 
rather than canine glaucoma. Different forms of canine 
glaucoma may respond differently to specific medications. 
For example, results of IOP studies performed in Beagle 
POAG may not translate to other forms of canine glaucoma. 
Furthermore, we have observed inter‐individual differences 
in dogs’ responsiveness to glaucoma drugs. Recent efforts are 
geared toward the development of mechanistic‐based thera-
pies with the hope that they would be more effective. Two 
topical IOP‐lowering medications recently approved by the 
US Food and Drug Administration (FDA) are latanoprostene 
bunod (Vyzulta™; Bausch & Lomb Incorporated) and netar-
sudil (Rhopressa™; Aerie Pharmaceuticals). Latanoprostene 
bunod is a nitric oxide‐donating prostaglandin F2α agonist 
with improved IOP‐lowering effect in ADAMTS10‐mutant 
beagles with POAG compared to latanoprost.25-27 The en-
hanced effectiveness of latanoprostene bunod is based on the 
beneficial effect on both uveoscleral and trabecular aqueous 
humor outflow.28 Netarsudil is a Rho kinase (ROCK) in-
hibitor and the first drug specifically designed to target the 
trabecular meshwork cells. Based on this mechanism of ac-
tion, the drug is expected to be more effective in POAG than 
PACG. ROCK inhibition reduces cell contractility and cell 
stiffness, and it decreases expression of fibrosis‐related pro-
teins, resulting in increased trabecular outflow facility.29-31 
In addition, netarsudil has norepinephrine transporter (NET) 
inhibitory activity, which may be responsible for the docu-
mented reduction of aqueous humor production and decrease 
in episcleral venous pressure, thereby further contributing to 
the lowering of IOP.29,32,33 Testing of netarsudil 0.02% oph-
thalmic solution (corresponding to commercial Rhopressa™) 
resulted in IOP reduction of ~5  mm  Hg in normal Dutch 
Belted rabbits and Formosan Rock monkeys, but there are no 
published reports on its effectiveness in dogs.29 Canine stud-
ies of netarsudil were limited to corneal metabolic assays, 
F I G U R E  2  Optical coherence tomography (OCT) images of 
the canine eye taken with the Spectralis® (Heidelberg Engineering 
GmbH, Heidelberg, Germany). A, Iridocorneal angle of a 2.5‐year 
old, female Beagle with POAG (IOP during imaging: 23 mm Hg). 
OCT often provides higher resolution than routine high‐resolution 
ultrasonography (Figure 3), but there are still limits when imaging 
deeper tissues, such as the aqueous humor outflow pathways (*). 
B, ONH images of a normal (B1; 6.5‐years old female) and POAG‐
affected (B2; 9.5‐years old female) Beagle. While the nondegenerated, 
well‐myelinated normal canine ONH bulges into the vitreous (B1; 
IOP during imaging: 15 mm Hg), the chronically glaucomatous 
ONH appears cupped (B2; IOP during imaging: 19 mm Hg). The 
white arrows indicate the location of the lamina cribrosa. Unless 
there is extensive degeneration, the canine lamina cribrosa is difficult 
to visualize, even with the current enhanced depth imaging (EDI) 
technology, due to the thick, myelinated prelaminar ONH. AC, anterior 




F I G U R E  3  High‐resolution ultrasound (HRUS) images of the 
canine iridocorneal angle. Compared to a normal eye with physiologic 
IOP (A) with flat iris and open ciliary cleft (white arrows), the iris has 
a sigmoidal shape with increased corneal contact (black arrow) and a 
collapsed ciliary cleft (white arrow) in an eye with acute PACG and 
IOP of 55 mm Hg (B). AC, anterior chamber; C, cornea; CB, ciliary 
body; I, iris. (From Miller143; with permission)
(A) (B)
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and the ROCK inhibitor Y27632 has been shown to stimu-
late corneal endothelial wound healing in normal dogs fol-
lowing experimental transcorneal freezing.29,34 Netarsudil 
has been combined with latanoprost (Roclatan™, Aerie 
Pharmaceuticals) with an improvement in IOP reduction in 
human patients with POAG or ocular hypertension.35
Poor adherence to eye drop administration is a major factor 
contributing to the progression of glaucomatous optic neurop-
athy in human patients. An estimated 50% of patients do not 
adhere to their medication over 75% of the time.36 In addition, 
only 60%‐70% of prescribed doses of eye drops are taken by 
glaucoma patients.37 Drug administration adherence in canine 
glaucoma has rarely been studied, but also could be a concern. 
In one study evaluating the capability of demecarium bromide 
or betaxolol to prevent/delay the onset of PACG in the normo-
tensive fellow eyes of dogs with unilateral PACG, 78%‐94% of 
clients self‐reported that they administered the medications at 
least 90% of the time, and 93%‐97% reported that they admin-
istered it at least 50% of the time.38 To address this problem in 
human patients, several drug companies have developed de-
vices for long‐term, sustained drug release, either onto the cor-
neal surface or into the anterior chamber. Most of these drug 
implants release prostaglandin analogs; some were moved 
from preclinical testing into clinical application in human pa-
tients. Externally placed devices include the OTX‐TP travo-
prost punctal plugs (Ocular Therapeutix, Inc) and the Helios™ 
bimatoprost periocular ring (Allergan plc) for placement into 
the conjunctival fornix.39,40 Intracameral implants include 
Bimatoprost SR (Allergan), ENV515 travoprost (Envisia 
Therapeutics, Inc), OTX‐TIC travoprost (Ocular Therapeutix, 
Inc), and iDose travoprost (Glaukos®).39,41 Intracameral, bio-
degradable latanoprost‐, bimatoprost‐, and travoprost‐releas-
ing devices have been tested successfully in normal dogs and 
dogs with POAG, but we are not aware of any plans to move 
these devices into veterinary clinical application.41-44 The use 
of ocular, slow‐releasing drug implants is not new in veteri-
nary ophthalmology since cyclosporine devices are being used 
in both horses and dogs for recurrent uveitis, immune‐medi-
ated keratitis, and keratoconjunctivitis sicca.45-47
Our discussions on medical management of canine glau-
coma also included the evaluation of compounds to decrease 
the rate of secondary glaucoma following phacoemulsifi-
cation surgery. The detailed functional and morphological 
assessment of the aqueous humor outflow pathways fol-
lowing canine cataract surgery should be continued (Figure 
4).48,49 The ability of cholinergics (eg, carbachol) or pros-
taglandin analogs (eg, latanoprost) to reverse some of the 
anatomic alterations in ciliary cleft morphology associated 
with lens extraction needs to be further evaluated in random-
ized and adequately powered, prospective clinical trials.50 
Additionally, there are clear indications that the formation of 
pre‐iridal fibrovascular membranes (PIFVMs) impairs aque-
ous humor drainage and elevates IOP.7 It is suspected that 
upregulation of vascular endothelial growth factor (VEGF) 
expression associated with lens‐induced uveitis is one of the 
factors resulting in PIFVM formation.51 The intravitreal ad-
ministration of anti‐VEGF compounds, such as ranibizumab 
(Lucentis®, Genentech, Roche Group) or bevacizumab 
(Avastin®, Genentech), is performed routinely in human 
patients with age‐related macular degeneration and diabetic 
retinopathy and also could be considered for the treatment 
of dogs following cataract surgery.52,53 These injections are 
mostly safe in human patients, but adverse effects, including 
immune‐mediated uveitis directed at a humanized protein 
and decrease in aqueous humor outflow facility, have been 
reported in few human patients and also observed by some 
of us following injection in canine eyes (unpublished).54-56 
Clearly, other anti‐neovascular strategies, such as gene ther-
apies, are needed to address some of these limitations in the 
dogs, including the need for repeated intraocular injections.57
Until specific therapeutic targets can be identified in dogs, 
the use of better anti‐inflammatory drugs may be the most 
promising option currently available. These drugs need to in-
hibit lens‐induced uveitis and re‐establish the blood‐aqueous 
barrier following cataract surgery. Compounds/methods that 
have been discussed, and are already used by some veteri-
nary ophthalmologists, include the intraocular administration 
of corticosteroids by injection or implant (eg, Retisert® flu-
ocinolone acetonide intravitreal implant, Bausch & Lomb), 
and highly potent steroidal and nonsteroidal anti‐inflamma-
tory ophthalmic solutions/suspensions, such as difluprednate 
(Durezol®, Alcon Laboratories, A Novartis Division) and 
nepafenac (Nevanac®, Alcon Laboratories), respectively. 
F I G U R E  4  The canine ciliary cleft may collapse following 
lens removal by phacoemulsification. Tissue cross‐sections of the 
iridocorneal angle in normal Bouin's fixed globes show that compared 
to the normal, unoperated eye (A) the ciliary cleft is severely reduced 
in an eye 24 h after phacoemulsification (B). The IOP in this eye 
reached 52 mm Hg 3 h after surgery and decreased to 15 mm Hg at 
24 h. Despite the normalization of IOP, the ciliary cleft remained 
reduced. The arrows denote the approximate boundaries of the ciliary 
cleft. Bars = 0.2 mm. (from Miller et al49; with permission)
(A) (B)
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Prospective randomized clinical trials are required to objec-
tively evaluate the effectiveness of these compounds in dogs.
5 |  NOVEL SURGICAL 
THERAPIES TO CONTROL IOP
The development of new glaucoma medications is slow, ar-
duous, costly, and optimized for the human rather than canine 
eye. Therefore, the improvement of surgical management of 
canine glaucoma may offer more promise in the foreseeable 
future for long‐term IOP control and sight preservation.
Currently, the most commonly used surgical techniques 
for canine glaucoma are placement of drainage implants 
to shunt aqueous humor to equatorial bleb‐promoting res-
ervoirs (Figure 5), cyclodestructive techniques to reduce 
aqueous humor production, and combinations of these two 
methods.58,59 Even though recently introduced surgical 
methods appear promising with increased success rates, 
they are often associated with intensive postoperative care 
and considerable expense, and a substantial number of af-
fected dogs still go blind. The method of choice is based on 
clinician preference and cost to owner, and is influenced by 
factors such as breed, type and stage of glaucoma, and sur-
geon experience. Based on these factors, long‐term success 
rates for IOP control and preservation of sight vary consid-
erably, but tend to improve with more advanced technol-
ogies and modifications of surgical techniques. The most 
recently published 1‐year success rates of canine glaucoma 
surgery for both IOP control and sight preservation are 
~90% for Ahmed valved drainage implants,21,60 65%‐75% 
for Baerveldt nonvalved glaucoma drainage device,61,62 
41%‐92% for transscleral cyclophotocoagulation (TSCP) 
alone or in combination with the placement of Ahmed 
valved drainage implants,62-67 and 72%‐74% for endolaser 
cyclophotocoagulation (ECP).58 Even though we have to 
be careful when comparing human and canine studies be-
cause of different study designs, inclusion/exclusion crite-
ria, and specific outcome measures, these canine success 
rates are comparable to published results in human patients 
for Ahmed and Baerveldt drainage devices (ClinicalTrials.
gov Identifier: NCT00376363).68 Most of the published ca-
nine studies are severely limited because of small sample 
size and short follow‐up period; these are shortcomings 
that need to be addressed in the future, for example, by 
taking advantage of multicenter studies. This has been rec-
ognized as a high priority during our discussions. The most 
common complications which can result in vision loss and 
which should be addressed in future research projects in-
clude ocular hypertension, intracameral fibrin formation, 
ocular hypotony and phthisis bulbi, cataract formation, and 
corneal ulceration.61,62 The confounding effect of inflam-
mation in canine eyes with PACG has to be considered in 
the development and improvement of surgical therapies.69
Improvements in implant design, surgical technique, mod-
ulation of wound healing, patient selection, and postoperative 
management, including IOP home monitoring to detect early 
implant failure, have resulted in improved success rates using 
the Ahmed valved device as a single surgical treatment op-
tion.21,60 Other drainage implants that are being used in dogs 
include Molteno and Baerveldt devices, as well as frontal 
sinus shunts.61,62,70 Scar formation over the subconjunctival 
bleb is one of the main reasons for implant failure in both 
human and canine patients. For reasons that remain to be 
determined, bleb fibrosis appears much more exaggerated in 
dogs than humans. Currently, the main approach to inhibit 
scar formation continues to be the intraoperative treatment 
of the bleb site with antimitotic compounds, such as mito-
mycin‐C (MMC) or 5‐fluorouracil (5‐FU).21,59,61,62 These 
reagents have to be handled with great care because of their 
potential toxic effect and possible conjunctival necrosis.59,60 
Whenever capsule fibrosis has developed and IOP starts to 
increase, repeated bleb revision of the overlying conjunctiva 
is indicated by removing a portion of the fibrotic capsule 
over the implant and/or injection of an antimitotic reagent 
such as 5‐FU.59 The search for new, improved anti‐fibrotic 
treatment strategies (“scar wars”) has been ongoing for many 
years and continues to be a high priority.71-74 The use of new 
compounds and molecular therapies are being considered for 
targeting of specific profibrotic molecular pathways.71-75
In humans, a two‐stage drainage implant technique is 
oftentimes useful to reduce complications related to hy-
potony and inflammation and may be applicable for some 
forms of canine glaucoma. This method was proposed 
in 1979 by Molteno et al.76 In the first stage, the epis-
cleral plate of the drainage device is positioned without 
F I G U R E  5  Tube positioning of an 
Ahmed VS‐2 valved drainage implant (New 
World Medical Inc, Rancho Cucomonga, 
CA, USA) in the anterior chamber of two 
dogs (A and B). B, Subconjunctival filtering 
bleb is shown underneath the upper eyelid
(A) (B)
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intracameral tube insertion. A capsule is allowed to form 
around the plate over ~6‐week period. Subsequently, the 
silicone tube is inserted into the anterior chamber during 
the second stage. The already formed capsule provides re-
sistance to aqueous outflow, allowing a more controlled 
IOP decrease.76
Despite the recent emergence of ECP (see below), diode 
laser TSCP is still widely used by veterinary ophthalmolo-
gists, either as a sole surgical tool or in combination with 
the placement of a drainage implant.21,60,63-67 While TSCP 
is relatively noninvasive and easy to perform, the long‐term 
success rate tends to be lower (50%‐92% IOP control and 
50%‐53% vision at 1‐year post‐TSCP), unless the laser treat-
ment is combined with drainage implants.58,59,63-65 Vision‐
threatening complications associated with conventional 
TSCP include immediate IOP elevation, corneal ulceration, 
retinal detachment, hemorrhage, and hypotony with resulting 
phthisis bulbi. Most of these adverse effects are due to the 
nonselective destruction of adjacent tissues because of the 
high temperatures reached in the target tissue.58,77 A novel 
technique currently being evaluated for TSCP is the use of 
micropulse laser (Figure 6; MicroPulse® Cyclo G6; Iridex).78 
The proposed main advantage of micropulse TSCP is the 
short wave of energy followed by an off cycle that allows 
the adjacent nonpigmented tissue to cool off, thereby mini-
mizing any collateral thermal damage to adjacent tissues.78,79 
The exact mechanism of action of micropulse TSCP still 
needs to be determined, but may consist not only of ciliary 
ablation but also improved conventional and uveoscleral 
aqueous humor outflow.78,79 Preliminary results about the 
effectiveness of the micropulse laser in dogs are mixed, with 
a need to refine protocols and patient selection to improve 
long‐term IOP‐lowering treatment effect and reduce the rate 
of complications, such as corneal ulceration.79,80
Diode ECP is an attractive alternative to TSCP in the 
treatment of canine glaucoma. It is combined with lens 
removal by phacoemulsification, or it also can be used for 
prophylactic treatment combined with cataract removal 
in dogs at increased risk of glaucoma development.58 
The main advantage of ECP over TSCP is that the ciliary 
processes and the laser treatment effect can be visualized 
directly through an endoscope, allowing the use of more 
controlled application of significantly less laser energy 
(Figure 7). Even though ECP has been used by veterinary 
ophthalmologists for over 10  years, peer‐reviewed publi-
cations of large case series are lacking and considered of 
high priority by our group. The use of laser cyclophotoco-
agulation may be potentially less effective in color‐diluted 
dogs with blue irises and no pigment in the ciliary muscu-
lature possibly resulting in less absorption of laser energy 
for photocoagulation.81
The introduction of microinvasive or minimally invasive 
glaucoma surgeries (MIGS) in the surgical management of 
open‐angle glaucoma in humans represents an innovative de-
velopment. The impact of the various MIGS remains to be 
determined with long‐term outcomes of effective IOP reduc-
tion and complications,  and with appropriate comparative 
effectiveness trials and meta‐analyses.82 Because of their 
minimal invasiveness with moderate IOP reductions, these 
aqueous humor draining techniques are being considered 
more often as alternatives for the treatment of early glau-
coma stages, instead of medical therapies.83 Even though 
MIGS are being developed specifically for human patients, 
some could be considered for application in dogs, especially 
if they are not targeting the Schlemm's canal which does 
not exist in canines. For example, the EX‐PRESS® Mini 
Glaucoma Shunt (Alcon, A Novartis Division) allows aque-
ous humor drainage from the anterior chamber beneath a 
scleral flap. Some of the authors as well as others have used 
the EX‐PRESS® Mini Glaucoma Shunt in selected cases in 
combination with ECP or cataract surgery for temporary IOP 
relief, with a 1‐year vision survival rate of up to 80% (Saito 
2018, personal communication).84 Other approved devices 
and techniques used in human patients include InnFocus 
MicroShunt® (InnFocus, Inc), iStent® (Glaukos®), and 
Gonioscopy‐Assisted Transluminal Trabeculotomy (GATT). 
The XEN® Gel Stent (Allergan Plc) is a microfistula implant 
that consists of a glutaraldehyde cross‐linked porcine gela-
tin tube that is placed ab interno under direct gonioscopic 
visualization from the anterior chamber through the trabec-
ular meshwork and sclera into the subconjunctival space; 
its biocompatibility was successfully tested over 1  year in 
normal Beagles, but we are not aware of any applications in 
glaucomatous dogs.85 Recently, the nanoengineered SalVO/
Brown Glaucoma Implant (MicroOptx) was proposed for 
use in dogs.86,87 This MIGS device drains aqueous humor 
onto the ocular surface, and it was safe and effective to lower 
IOP in normal Yucatan pigs.87 Safety and efficacy remain to 
be determined in humans and dogs.
F I G U R E  6  Positioning of the MicroPulse® Cyclo G6 probe 
(Iridex) 3 mm posterior to the limbus of a dog during transscleral 
cyclophotocoagulation (TSCP)
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6 |  NOVEL TREATMENT 
STRATEGIES FOR THE FUTURE
6.1 | Gene and stem cell therapies to control 
IOP
Major advances have been made over the past 20  years 
in ocular gene therapy, and a few retinal and optic nerve 
treatments have been translated into clinical application 
for human patients.57,88,89 We anticipate that gene therapy 
of both the anterior and posterior segments of the eye will 
eventually benefit glaucoma patients. The identification 
of molecular disease pathways and genetic risk factors af-
fecting the aqueous humor outflow pathways will allow 
us to target and correct the disease pathogenesis very 
specifically, potentially resulting in long‐term, effective 
IOP control. Major advances in this direction already have 
been made by robust and safe targeting of transgene ex-
pression to the trabecular meshwork in several animal spe-
cies, including dogs: Treatment has been done by aqueous 
paracentesis and intracameral administration of adenovi-
rus, lentivirus, and adeno‐associated virus (AAV) gene 
therapy vectors.90-94 The recent development of novel cap-
sid mutated virus particles resulted in an expanded AAV 
vector toolkit for targeting of the trabecular meshwork and 
other tissues within the anterior segment of the eye that 
may contribute to increased aqueous humor outflow re-
sistance in glaucoma.91,93-95 The good safety and efficacy 
record of AAV within the eye renders it a very attractive 
option for therapy and long‐term IOP control in primary 
glaucoma.
Recently, trabecular meshwork‐like cells were created 
from induced pluripotent stem cells (iPSCs) and injected into 
the anterior chamber of transgenic, myocilin (MYOC)‐mutant 
mice with POAG.96,97 Subsequently, the conventional out-
flow pathway was replenished with new TM cells, resulting 
in improved outflow facility, IOP control, and halted RGC 
loss, even in animals with advanced stages of glaucoma.96,97 
These proof‐of‐concept studies indicate that stem cell‐based 
therapy also may become an option for long‐term IOP control 
in dogs with primary glaucoma.
6.2 | Modification of the eye's 
biomechanical properties
The biomechanical properties of the eye, most importantly its fi-
brous layer (cornea, sclera, and lamina cribrosa), determine the 
susceptibility to various levels of IOP.98 Even physiologic IOP 
can damage RGC axons as they pass through the lamina cribrosa 
if the surrounding connective tissue does not provide the neces-
sary protective support. This may contribute to the disease pro-
cess in nearly half of human patients with open‐angle glaucoma 
who are normotensive with IOP measurements consistently 
lower than 21mmHg.99,100 A 30% IOP reduction in these nor-
motensive glaucoma patients can prevent progression of visual 
field loss.101 As veterinary ophthalmologists we have a unique 
opportunity to study how the biomechanical properties of the 
ocular tissues affect susceptibility to IOP. For example, we ob-
serve that ADAMTS10‐mutant beagles102 and ADAMTS17‐mu-
tant Chinese shar‐peis103 with POAG maintain eye sight longer 
with slower progression of ONH atrophy than many other 
glaucomatous dog breeds with comparable pressures.16 While 
proof still needs to be provided that tissue properties are linked 
to IOP susceptibility in dogs, initial biomechanical studies in 
ADAMTS10‐mutant beagles showed that their posterior sclera is 
weaker with reduced fibrous collagen density.104-106 Similarly, 
some genetically altered mice are resistant to glaucoma damage, 
while treatment of the sclera with cross‐linking agents worsens 
IOP‐related damage to the RGC axons.98 Once we define ad-
vantageous biomechanical properties of the fibrous layer of the 
eye, therapeutic tools can be developed to modify these proper-
ties in order to achieve a protective effect.
6.3 | Neuroprotection
The final common pathway of all forms of glaucoma is the 
progressive loss of RGCs and their axons, even when IOP is 
effectively controlled. Considerable effort has been put into 
the study of IOP‐independent disease mechanisms responsi-
ble for RGC death in animal models and human patients, so 
that neuroprotective treatments can be developed. Some of 
these disease pathways, which may or may not be triggered 
F I G U R E  7  Endolaser cyclophotocoagulation (ECP) in the canine eye. A, The laser endoscope is inserted through a limbal incision and 
the pupil to access the ciliary processes. The endoscopic view shows the red aiming beam on the ciliary processes before (B) and following laser 
treatment when they appear white and shrunken (C). The lens capsule is shown on the bottom and the posterior iris surface on the top (B and C)
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by IOP, include: excitotoxicity caused by excessive excita-
tory amino acid release, such as glutamate and aspartate107,108; 
neurotrophin deprivation from blockage of retrograde axonal 
transport109-112; excessive intracellular calcium113; compro-
mised blood flow to the ONH and retina114-120; oxidative 
stress121,122; inflammation and autoimmunity against retinal 
and optic nerve antigens123-125; and reactive gliosis.126-129 
Unfortunately, most of these mechanisms have not yet been 
investigated in dogs, and there may be profound species dif-
ferences. For example, the unique vascular anatomy in dogs 
may render their retina and ONH more susceptible to is-
chemia with IOP variation.130
While many available compounds address some of these 
previously listed disease pathways resulting in significant 
RGC protection in experimental animal models of glaucoma, 
none of them has been moved successfully into clinical ap-
plication. Two neuroprotective therapies that have under-
gone clinical trials for glaucoma are memantine, given by 
oral route, and ciliary neurotrophic factor (CNTF), contin-
uously released into the vitreous (Figure 8). Memantine is 
an N methyl‐D aspartate (NMDA) receptor antagonist that 
counters the toxic effect of excessive glutamate in the ex-
tracellular space; it is used traditionally for the treatment 
of Alzheimer's disease. Memantine reduces RGC death and 
functional loss in experimental glaucoma in rats and pri-
mates.131-133 Unfortunately, protection of visual function by 
memantine could not be demonstrated in human glaucoma 
patients enrolled in two phase 3 clinical trials.134 The intra-
vitreal administration of CNTF reportedly slows RGC death 
in rats with experimental glaucoma.135 The continuous re-
lease of CNTF by intravitreal encapsulated cell therapy 
was tested recently in phase 1 clinical trials in patients with 
POAG (ClinicalTrials.gov NCT01408472) and ischemic 
optic neuropathy (NCT01411657), but results have not yet 
been published. Some veterinary ophthalmologists, including 
some authors of this article, are using the calcium channel 
blocker amlodipine systemically in selected canine glaucoma 
patients based on its documented beneficial effects on ocular 
blood flow in normal dogs and potential neuroprotection.136 
Currently, there is no data showing advantages of amlodipine 
in glaucomatous dogs, and it is possible that the blood pres-
sure lowering effect of the drug may negatively affect ocu-
lar perfusion pressure. The development of neuroprotective 
therapies for glaucoma continues to be a high‐priority goal, 
which may also take advantage of tools such as gene and stem 
cell therapies.137,138
6.4 | Neuroregeneration
In mammals, RGCs do not regenerate once they are lost; 
this is contrary to other classes of animals, such as fish 
and amphibians, where retina and optic nerve can regener-
ate naturally. A number of animal studies have shown that 
under the right circumstances, mammalian RGCs are able 
to regenerate their axons and connect to the proper targets 
within the brain, resulting in some functional recovery of 
eye sight.139,140 The replacement of lost RGCs and the re-
generation of their axons are high priorities in glaucoma 
research, and our dog patients may also benefit from these 
efforts in the future. The National Eye Institute (NEI) within 
the National Institutes of Health (NIH) predicts that these 
goals are achievable within 10‐15 years and has made them 
high priorities for research funding.141 Furthermore, trans-
plantation of RGCs by intravitreal injection is one method 
to replace lost RGCs.142 Ultimately, even transplantation of 
whole eyes may become an option with improvements in 
optic nerve regeneration.
7 |  SUMMARY
While much progress has been made in the understanding and 
treatment of canine glaucoma, there is still no cure and many 
affected dogs go blind. The improved knowledge of disease 
mechanisms and the development of reliable biomarkers are 
critical so that animals at risk or in early stages of disease 
can be identified more readily. Early diagnosis facilitates ef-
fective, mechanism‐based treatment before the occurrence 
of any clinically appreciable optic nerve damage and vision 
loss. To achieve these goals, we recommend research priori-
ties for clinicians and basic scientists. One of the main limita-
tions in these efforts is the scarcity of major research funding 
specifically dedicated to canine disease.
ACKNOWLEDGMENTS
The Canine Glaucoma Think Tank and Consortium 
were supported by the American College of Veterinary 
F I G U R E  8  Sustained intraocular delivery of ciliary neurotrophic 
factor (CNTF) by encapsulated cell technology (ECT) in a canine 
eye. The NT‐501 implant containing CNTF‐secreting human cells 
(Neurotech Pharmaceuticals, Inc) is located within the vitreous and 
anchored to the pars plana of the ciliary body
736 |   KOMÁROMY et al.
Ophthalmologists Vision for Animals Foundation (ACVO‐
VAF). Additional funding of the authors' glaucoma re-
search was provided by the ACVO‐VAF (AMK), Bouvier 
Health Foundation (PEM), BrightFocus Foundation (AMK: 
G2017185), Michigan State University College of Veterinary 
Medicine Endowed Research Funds (AMK), and National 
Eye Institute/National Institutes of Health (AMK: R01‐
EY025752; SEM: R01‐EY022124).
CONFLICTS OF INTEREST
The authors have the following potential conflicts of inter-
est (in alphabetic order): Aerie Pharmaceutical (RLF and 
SEM: research funding, clinical trial grant), Allergan (SEM: 
research funding, clinical trial grant), Bausch and Lomb 
(RLF: research funding), Beaver‐Visitec (RLF: consultant), 
Cara Life (DWE: previous consultant), Elsevier (PEM: book 
royalties), Ivantis (CBT: research funding), Nicox (CBT: 
research funding), OSOD (PEM: consultant), PolyActiva 
(AMK: research funding), Santen (CBT: research funding), 
and Wolters Kluwer (SEM: book royalties). The opinions ex-
pressed in this article are the authors' own and do not neces-
sarily reflect  the view of the United States Food and Drug 
Administration (FDA) or the  United States  Government. 
Special thanks go to Ms. Jen Gazdacko (ACVO‐VAF) for 
her technical support.
ORCID
András M. Komáromy   https://orcid.
org/0000-0002-8845-0588 
Larry Kagemann   https://orcid.org/0000-0001-8961-0187 
Caryn E. Plummer   https://orcid.
org/0000-0003-0917-4130 
Leandro B. Teixeira   https://orcid.
org/0000-0001-9960-678X 
Carol B. Toris   https://orcid.org/0000-0003-3794-6142 
REFERENCES
 1. Gelatt KN, MacKay EO. Prevalence of the breed‐related glau-
comas in pure‐bred dogs in North America. Vet Ophthalmol. 
2004;7:97‐111.
 2. Gelatt KN, MacKay EO. Secondary glaucomas in the dog in 
North America. Vet Ophthalmol. 2004;7:245‐259.
 3. Quigley HA, Broman AT. The number of people with glaucoma 
worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262‐267.
 4. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma 
and projections of glaucoma burden through 2040: a systematic 
review and meta‐analysis. Ophthalmology. 2014;121:2081‐2090.
 5. Newbold GM, Kelch WJ, Chen T, et al. Phacoemulsification out-
comes in Boston terriers as compared to non‐Boston terriers: a ret-
rospective study (2002–2015). Vet Ophthalmol. 2018;21:353‐361.
 6. Foote BC, Pederson SL, Welihozkiy A, et al. Retinal detach-
ment and glaucoma in the Boston Terrier and Shih Tzu following 
phacoemulsification (135 patients): 2000–2014. Vet Ophthalmol. 
2018;21:240‐248.
 7. Scott EM, Esson DW, Fritz KJ, et al. Major breed distribution 
of canine patients enucleated or eviscerated due to glaucoma 
following routine cataract surgery as well as common histo-
pathologic findings within enucleated globes. Vet Ophthalmol. 
2013;16(Suppl 1):64‐72.
 8. Moeller E, Blocker T, Esson D, et al. Postoperative glaucoma in 
the Labrador Retriever: incidence, risk factors, and visual out-
come following routine phacoemulsification. Vet Ophthalmol. 
2011;14:385‐394.
 9. Sigle KJ, Nasisse MP. Long‐term complications after phacoemul-
sification for cataract removal in dogs: 172 cases (1995–2002). J 
Am Vet Med Assoc. 2006;228:74‐79.
 10. Biros DJ, Gelatt KN, Brooks DE, et al. Development of glaucoma 
after cataract surgery in dogs: 220 cases (1987–1998). J Am Vet 
Med Assoc. 2000;216:1780‐1786.
 11. Lannek EB, Miller PE. Development of glaucoma after 
phacoemulsification for removal of cataracts in dogs: 22 cases 
(1987–1997). J Am Vet Med Assoc. 2001;218:70‐76.
 12. Weinreb RN, Aung T, Medeiros FA. The pathophysiol-
ogy and treatment of glaucoma: a review. J Am Med Assoc. 
2014;311:1901‐1911.
 13. Tsai S, Almazan A, Lee SS, et al. The effect of topical latanoprost 
on anterior segment anatomic relationships in normal dogs. Vet 
Ophthalmol. 2013;16:370‐376.
 14. Tsai S, Miller PE, Struble C, et al. Topical application of 0.005% 
latanoprost increases episcleral venous pressure in normal dogs. 
Vet Ophthalmol. 2012;15(Suppl 1):71‐78.
 15. Dubin AJ, Bentley E, Buhr KA, et al. Evaluation of potential risk 
factors for development of primary angle‐closure glaucoma in 
Bouviers des Flandres. J Am Vet Med Assoc. 2017;250:60‐67.
 16. Grozdanic SD, Kecova H, Harper MM, et al. Functional and 
structural changes in a canine model of hereditary primary angle‐
closure glaucoma. Invest Ophthalmol Vis Sci. 2010;51:255‐263.
 17. Hasegawa T, Kawata M, Ota M. Ultrasound biomicroscopic find-
ings of the iridocorneal angle in live healthy and glaucomatous 
dogs. J Vet Med Sci. 2016;77:1625‐1631.
 18. Kagemann L, Wollstein G, Ishikawa H, et al. Visualization 
of the conventional outflow pathway in the living human eye. 
Ophthalmology. 2012;119:1563‐1568.
 19. Kagemann L, Wollstein G, Ishikawa H, et al. 3D visualization 
of aqueous humor outflow structures in‐situ in humans. Exp Eye 
Res. 2011;93:308‐315.
 20. Almazan A, Tsai S, Miller PE, et al. Iridocorneal angle measure-
ments in mammalian species: normative data by optical coher-
ence tomography. Vet Ophthalmol. 2013;16:163‐166.
 21. Saito A, Kazama Y, Iwashita H, et al. Outcome of anterior 
chamber shunt procedure in 104 eyes of dogs (abstract). 48th 
Annual Conference of the American College of Veterinary 
Ophthalmologists. 2017;41.
 22. Meier‐Gibbons F, Berlin MS, Toteberg‐Harms M. Twenty‐four 
hour intraocular pressure measurements and home tonometry. 
Curr Opin Ophthalmol. 2018;29:111‐115.
 23. Komaromy AM, Petersen‐Jones SM. Genetics of canine pri-
mary glaucomas. Vet Clin North Am Small Anim Pract. 
2015;45:1159‐1182.
   | 737KOMÁROMY et al.
 24. Graham KL, McCowan C, White A. Genetic and biochemical bio-
markers in canine glaucoma. Vet Pathol. 2017;54:194‐203.
 25. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypoten-
sive activity of BOL‐303259‐X, a nitric oxide donating pros-
taglandin F2alpha agonist, in preclinical models. Exp Eye Res. 
2011;93:250‐255.
 26. Borghi V, Bastia E, Guzzetta M, et al. A novel nitric oxide re-
leasing prostaglandin analog, NCX 125, reduces intraocular 
pressure in rabbit, dog, and primate models of glaucoma. J Ocul 
Pharmacol Ther. 2010;26:125‐132.
 27. Impagnatiello F, Borghi V, Gale DC, et al. A dual acting com-
pound with latanoprost amide and nitric oxide releasing proper-
ties, shows ocular hypotensive effects in rabbits and dogs. Exp 
Eye Res. 2011;93:243‐249.
 28. Cavet ME, DeCory HH. The role of nitric oxide in the intraocu-
lar pressure lowering efficacy of latanoprostene bunod: review of 
nonclinical studies. J Ocul Pharmacol Ther. 2017;34:52‐60.
 29. Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical 
development of netarsudil, a novel ocular hypotensive agent for the 
treatment of glaucoma. J Ocul Pharmacol Ther. 2017;34:40‐51.
 30. Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho 
GTPase/Rho kinase signaling pathway in pathogenesis and treat-
ment of glaucoma: Bench to bedside research. Exp Eye Res. 
2017;158:23‐32.
 31. Wang SK, Chang RT. An emerging treatment option for 
glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 
2014;8:883‐890.
 32. Rao PV, Deng PF, Kumar J, et al. Modulation of aqueous humor 
outflow facility by the Rho kinase‐specific inhibitor Y‐27632. 
Invest Ophthalmol Vis Sci. 2001;42:1029‐1037.
 33. Kiel JW, Kopczynski CC. Effect of AR‐13324 on episcleral ve-
nous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther. 
2015;31:146‐151.
 34. Miyagi H, Kim S, Li J, et al. Topical Rho‐associated kinase in-
hibitor, Y27632, accelerates corneal endothelial regeneration in a 
canine cryoinjury model. Cornea. 2019;38:352‐359.
 35. Lewis RA, Levy B, Ramirez N, et al. Fixed‐dose combination 
of AR‐13324 and latanoprost: a double‐masked, 28‐day, ran-
domised, controlled study in patients with open‐angle glaucoma 
or ocular hypertension. Br J Ophthalmol. 2016;100:339‐344.
 36. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with top-
ical glaucoma medication monitored electronically the Travatan 
Dosing Aid study. Ophthalmology. 2009;116:191‐199.
 37. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims 
data to study adherence to glaucoma medications: methodology 
and findings of the Glaucoma Adherence and Persistency Study 
(GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052‐5057.
 38. Miller PE, Schmidt GM, Vainisi SJ, et al. The efficacy of topical 
prophylactic antiglaucoma therapy in primary closed angle glau-
coma in dogs: a multicenter clinical trial. J Am Anim Hosp Assoc. 
2000;36:431‐438.
 39. Aref AA. Sustained drug delivery for glaucoma: current data and 
future trends. Curr Opin Ophthalmol. 2017;28:169‐174.
 40. Brandt JD, DuBiner HB, Benza R, et al. Long‐term safety 
and efficacy of a sustained‐release bimatoprost ocular ring. 
Ophthalmology. 2017;124:1565‐1566.
 41. Lee SS, Burke J, Shen J, et al. Bimatoprost sustained‐release in-
tracameral implant reduces episcleral venous pressure in dogs. Vet 
Ophthalmol. 2018;21:376‐381.
 42. Komaromy AM, Koehl KL, Harman CD, et al. Long‐term intra-
ocular Pressure (IOP) control by means of a novel biodegradable 
intracameral (IC) latanoprost free acid (LFA) implant (abstract). 
Annual Meeting of the Association for Research in Vision and 
Ophthalmology. 2017;58:4591.
 43. Robeson R, Verhoeven RS, Garcia A, et al. A 12‐month study of 
the ENV515 (travoprost) intracameral implant on intraocular pres-
sure in beagle dogs (abstract). Annual Meeting of the Association 
for Research in Vision and Ophthalmology.2017;58:1072.
 44. Seal JR, Robinson MR, Burke J, et al. Intracameral sustained‐
release bimatoprost implant delivers bimatoprost to target tis-
sues with reduced drug exposure to off‐target tissues. J Ocul 
Pharmacol Ther 2018;35:50‐57.
 45. Barachetti L, Rampazzo A, Mortellaro CM, et al. Use of epis-
cleral cyclosporine implants in dogs with keratoconjunctivitis 
sicca: pilot study. Vet Ophthalmol. 2015;18:234‐241.
 46. Gilger BC, Wilkie DA, Clode AB, et al. Long‐term outcome 
after implantation of a suprachoroidal cyclosporine drug de-
livery device in horses with recurrent uveitis. Vet Ophthalmol. 
2010;13:294‐300.
 47. Gilger BC, Stoppini R, Wilkie DA, et al. Treatment of immune‐
mediated keratitis in horses with episcleral silicone matrix cy-
closporine delivery devices. Vet Ophthalmol. 2014;17(Suppl 
1):23‐30.
 48. Rose MD, Mattoon JS, Gemensky‐Metzler AJ, et al. Ultrasound 
biomicroscopy of the iridocorneal angle of the eye before and 
after phacoemulsification and intraocular lens implantation in 
dogs. Am J Vet Res. 2008;69:279‐288.
 49. Miller PE, Stanz KM, Dubielzig RR, et al. Mechanisms of acute 
intraocular pressure increases after phacoemulsification lens ex-
traction in dogs. Am J Vet Res. 1997;58:1159‐1165.
 50. Stuhr CM, Miller PE, Murphy CJ, et al. Effect of intracameral 
administration of carbachol on the postoperative increase in intra-
ocular pressure in dogs undergoing cataract extraction. J Am Vet 
Med Assoc. 1998;212:1885‐1888.
 51. Sandberg CA, Herring IP, Huckle WR, et al. Aqueous humor 
vascular endothelial growth factor in dogs: association with in-
traocular disease and the development of pre‐iridal fibrovascular 
membrane. Vet Ophthalmol. 2012;15(Suppl 1):21‐30.
 52. Lim LS, Mitchell P, Seddon JM, et al. Age‐related macular degen-
eration. Lancet. 2012;379:1728‐1738.
 53. Simunovic MP, Maberley DA. Anti‐vascular endothelial growth 
factor therapy for proliferative diabetic retinopathy: A systematic 
review and meta‐analysis. Retina. 2015;35:1931‐1942.
 54. Wen JC, Reina‐Torres E, Sherwood JM, et al. Intravitreal anti‐
VEGF injections reduce aqueous outflow facility in patients with 
neovascular age‐related macular degeneration. Invest Ophthalmol 
Vis Sci. 2017;58:1893‐1898.
 55. Biagi C, Conti V, Montanaro N, et al. Comparative safety profiles 
of intravitreal bevacizumab, ranibizumab and pegaptanib: the 
analysis of the WHO database of adverse drug reactions. Eur J 
Clin Pharmacol. 2014;70:1505‐1512.
 56. Cunningham MA, Tlucek P, Folk JC, et al. Sequential, acute 
noninfectious uveitis associated with separate intravitreal injec-
tions of bevacizumab and ranibizumab. Retin Cases Brief Rep. 
2013;7:355‐358.
 57. Campochiaro PA, Lauer AK, Sohn EH, et al. Lentiviral vector 
gene transfer of endostatin/angiostatin for macular degeneration 
(GEM) study. Hum Gene Ther. 2017;28:99‐111.
738 |   KOMÁROMY et al.
 58. Bras D, Maggio F. Surgical treatment of canine glaucoma: cy-
clodestructive techniques. Vet Clin North Am Small Anim Pract. 
2015;45:1283‐1305.
 59. Maggio F, Bras D. Surgical treatment of canine glaucoma: filter-
ing and end‐stage glaucoma procedures. Vet Clin North Am Small 
Anim Pract. 2015;45:1261‐1282.
 60. Westermeyer HD, Hendrix DV, Ward DA. Long‐term eval-
uation of the use of Ahmed gonioimplants in dogs with pri-
mary glaucoma: nine cases (2000–2008). J Am Vet Med Assoc. 
2011;238:610‐617.
 61. Graham KL, Donaldson D, Billson FA, et al. Use of a 350‐mm2 
Baerveldt glaucoma drainage device to maintain vision and con-
trol intraocular pressure in dogs with glaucoma: a retrospective 
study (2013–2016). Vet Ophthalmol. 2017;20:427‐434.
 62. Graham KL, Hall E, Caraguel C, et al. Comparison of diode 
laser trans‐scleral cyclophotocoagulation versus implantation of 
a 350‐mm(2) Baerveldt glaucoma drainage device for the treat-
ment of glaucoma in dogs (a retrospective study: 2010–2016). Vet 
Ophthalmol. 2018;21:487‐497.
 63. Cook C, Davidson M, Brinkmann M, et al. Diode laser transscleral 
cyclophotocoagulation for the treatment of glaucoma in dogs: re-
sults of six and twelve month follow‐up. Vet Comp Ophthalmol. 
1997;7:148‐154.
 64. Hardman C, Stanley RG. Diode laser transscleral cyclophotoco-
agulation for the treatment of primary glaucoma in 18 dogs: a 
retrospective study. Vet Ophthalmol. 2001;4:209‐215.
 65. O'Reilly A, Hardman C, Stanley RG. The use of transscleral cy-
clophotocoagulation with a diode laser for the treatment of glau-
coma occurring post intracapsular extraction of displaced lenses: 
a retrospective study of 15 dogs (1995–2000). Vet Ophthalmol. 
2003;6:113‐119.
 66. Sapienza JS, van der Woerdt A. Combined transscleral diode laser 
cyclophotocoagulation and Ahmed gonioimplantation in dogs 
with primary glaucoma: 51 cases (1996–2004). Vet Ophthalmol. 
2005;8:121‐127.
 67. Bentley E, Miller PE, Murphy CJ, et al. Combined cycloablation 
and gonioimplantation for treatment of glaucoma in dogs: 18 
cases (1992–1998). J Am Vet Med Assoc. 1999;215:1469‐1472.
 68. Budenz DL, Barton K, Gedde SJ, et al. Five‐year treatment out-
comes in the Ahmed Baerveldt comparison study. Ophthalmology. 
2015;122:308‐316.
 69. Reilly CM, Morris R, Dubielzig RR. Canine goniodysgene-
sis‐related glaucoma: a morphologic review of 100 cases look-
ing at inflammation and pigment dispersion. Vet Ophthalmol. 
2005;8:253‐258.
 70. Cullen CL, Allen AL, Grahn BH. Anterior chamber to frontal 
sinus shunt for the diversion of aqueous humor: a pilot study in 
four normal dogs. Vet Ophthalmol. 1998;1:31‐39.
 71. Esson DW, Neelakantan A, Iyer SA, et al. Expression of connec-
tive tissue growth factor after glaucoma filtration surgery in a rab-
bit model. Invest Ophthalmol Vis Sci. 2004;45:485‐491.
 72. Esson DW, Popp MP, Liu L, et al. Microarray analysis of the fail-
ure of filtering blebs in a rat model of glaucoma filtering surgery. 
Invest Ophthalmol Vis Sci. 2004;45:4450‐4462.
 73. Yu‐Wai‐Man C, Spencer‐Dene B, Lee R, et al. Local delivery of 
novel MRTF/SRF inhibitors prevents scar tissue formation in a 
preclinical model of fibrosis. Sci Rep. 2017;7:518.
 74. Martorana GM, Schaefer JL, Levine MA, et al. Sequential therapy 
with saratin, bevacizumab and ilomastat to prolong bleb function 
following glaucoma filtration surgery in a rabbit model. PLoS 
ONE. 2015;10:e0138054.
 75. Sriram S, Robinson P, Pi L, et al. Triple combination of siRNAs 
targeting TGFbeta1, TGFbetaR2, and CTGF enhances reduction 
of collagen I and smooth muscle actin in corneal fibroblasts. 
Invest Ophthalmol Vis Sci. 2013;54:8214‐8223.
 76. Molteno AC, Van Biljon G, Ancker E. Two‐stage insertion 
of glaucoma drainage implants. Trans Ophthalmol Soc N Z. 
1979;31:17‐26.
 77. Nadelstein B, Wilcock B, Cook C, et al. Clinical and histiologic 
effects of diode transscleral cyclophotocoagulation in the normal 
canine eye. Vet Comp Ophthalmol. 1997;7:155‐162.
 78. Lee JH, Shi Y, Amoozgar B, et al. Outcome of micropulse laser 
transscleral cyclophotocoagulation on pediatric versus adult glau-
coma patients. J Glaucoma. 2017;26:936‐939.
 79. Sapienza JS, Kim K, Rodriguez E, DiGirolamo N. Preliminary 
findings in 30 dogs treated with micropulse transscleral cyclo-
photocoagulation for refractory glaucoma. Vet Ophthalmol. 2018; 
https ://doi.org/10.1111/vop.12622 . [Epub ahead of print].
 80. Sebbag L, Allbaugh RA, Strauss RA, et al. MicroPulse™ transs-
cleral cyclophotocoagulation in the treatment of canine glaucoma: 
Preliminary results (12 dogs). Vet Ophthalmol 2018. https ://doi.
org/10.1111/vop.12603 [Epub ahead of print].
 81. Newkirk KM, Haines DK, Calvarese ST, et al. Distribution and 
amount of pigment within the ciliary body and iris of dogs with 
blue and brown irides. Vet Ophthalmol. 2010;13:76‐80.
 82. Lavia C, Dallorto L, Maule M, et al. Minimally‐invasive glau-
coma surgeries (MIGS) for open angle glaucoma: a systematic 
review and meta‐analysis. PLoS ONE. 2017;12:e0183142.
 83. Fingeret M, Dickerson JE Jr. The role of minimally invasive glau-
coma surgery devices in the management of glaucoma. Optom Vis 
Sci. 2018;95:155‐162.
 84. Lutz EA, Sapienza JS. Combined diode endoscopic cyclopho-
tocoagulation and Ex‐Press™ shunt gonioimplantation in four 
cases canine glaucoma (abstract). 40th Annual Conference of the 
American College of Veterinary Ophthalmologists. 2009;80.
 85. Shute TS, Dietrich UM, Baker JF, et al. Biocompatibility of 
a novel microfistula implant in nonprimate mammals for the 
surgical treatment of glaucoma. Invest Ophthalmol Vis Sci. 
2016;57:3594‐3600.
 86. Larocca RD, Martin RC. Early results of the veterinary implant 
glaucoma registry (VIGOR) a multicenter evaluation of the Brown 
glaucoma implant in canines (abstract). 49th Annual Conference 
of the American College of Veterinary Ophthalmologists. 
2018;137.
 87. Martin RC, Baker SR, Render JA, et al. Safety and efficacy eval-
uation of a nanoengineered, externally comunicating, aqueous 
humor shunt in Yucatan swine (abstract). 49th Annual Conference 
of the American College of Veterinary Ophthalmologists. 
2018;136.
 88. Guy J, Feuer WJ, Davis JL, et al. Genet for Leber hereditary optic 
neuropathy: low‐ and medium‐dose visual results. Ophthalmology. 
2017;124:1621‐1634.
 89. Bennett J. Taking stock of retinal gene therapy: looking back and 
moving forward. Mol Ther. 2017;25:1076‐1094.
 90. Buie LK, Rasmussen CA, Porterfield EC, et al. Self‐comple-
mentary AAV virus (scAAV) safe and long‐term gene transfer 
in the trabecular meshwork of living rats and monkeys. Invest 
Ophthalmol Vis Sci. 2010;51:236‐248.
   | 739KOMÁROMY et al.
 91. Bogner B, Boye SL, Min SH, et al. Capsid mutated adeno‐as-
sociated virus delivered to the anterior chamber results in effi-
cient transduction of trabecular meshwork in mouse and rat. PLoS 
ONE. 2015;10:e0128759.
 92. Dang Y, Loewen R, Parikh HA, et al. Gene transfer to the outflow 
tract. Exp Eye Res. 2017;158:73‐84.
 93. Wang L, Xiao R, Andres‐Mateos E, et al. Single stranded adeno‐
associated virus achieves efficient gene transfer to anterior seg-
ment in the mouse eye. PLoS ONE. 2017;12:e0182473.
 94. Oh A, Harman CD, Koehl K, et al. Targeting of gene expression to 
the wildtype and ADAMTS10‐mutant canine trabecular meshwork 
by non‐self‐complementary AAV2 (abstract). Annual Meeting of the 
Association for Research in Vision and Ophthalmology. 2014;55:5669.
 95. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: 
poised at the clinical crossroads. Mol Ther. 2012;20:699‐708.
 96. Zhu W, Gramlich OW, Laboissonniere L, et al. Transplantation 
of iPSC‐derived TM cells rescues glaucoma phenotypes in vivo. 
Proc Natl Acad Sci USA. 2016;113:E3492‐E3500.
 97. Zhu W, Jain A, Gramlich OW, et al. Restoration of aqueous humor 
outflow following transplantation of iPSC‐derived trabecular 
meshwork cells in a transgenic mouse model of glaucoma. Invest 
Ophthalmol Vis Sci. 2017;58:2054‐2062.
 98. Quigley HA. The contribution of the sclera and lamina cribrosa to 
the pathogenesis of glaucoma: diagnostic and treatment implica-
tions. Prog Brain Res. 2015;220:59‐86.
 99. Sommer A, Tielsch JM, Katz J, et al. Relationship between in-
traocular pressure and primary open angle glaucoma among 
white and black Americans. The Baltimore Eye Survey. Arch 
Ophthalmol. 1991;109:1090‐1095.
 100. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. 
The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499‐1504.
 101. Collaborative Normal‐Tension Glaucoma Study Group. 
Comparison of glaucomatous progression between untreated 
patients with normal‐tension glaucoma and patients with ther-
apeutically reduced intraocular pressures. Am J Ophthalmol. 
1998;126:487‐497.
 102. Kuchtey J, Olson LM, Rinkoski T, et al. Mapping of the disease 
locus and identification of ADAMTS10 as a candidate gene in 
a canine model of primary open angle glaucoma. PLoS Genet. 
2011;7:e1001306.
 103. Oliver J, Rustidge S, Pettitt L, et al. Evaluation of ADAMTS17 
in Chinese Shar‐Pei with primary open‐angle glaucoma, primary 
lens luxation, or both. Am J Vet Res. 2018;79:98‐106.
 104. Boote C, Palko JR, Sorensen T, et al. Changes in posterior scleral 
collagen microstructure in canine eyes with an ADAMTS10 muta-
tion. Mol Vis. 2016;22:503‐517.
 105. Palko JR, Iwabe S, Pan X, et al. Biomechanical properties and 
correlation with collagen solubility profile in the posterior sclera 
of canine eyes with an ADAMTS10 mutation. Invest Ophthalmol 
Vis Sci. 2013;54:2685‐2695.
 106. Palko JR, Morris HJ, Pan X, et al. Influence of age on ocular 
biomechanical properties in a canine glaucoma model with 
ADAMTS10 mutation. PLoS ONE. 2016;11:e0156466.
 107. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling 
pathways for therapeutic intervention in glaucoma. Prog Brain 
Res. 2008;173:495‐510.
 108. Brooks DE, Garcia GA, Dreyer EB, et al. Vitreous body glu-
tamate concentration in dogs with glaucoma. Am J Vet Res. 
1997;58:864‐867.
 109. Pease ME, McKinnon SJ, Quigley HA, et al. Obstructed axonal 
transport of BDNF and its receptor TrkB in experimental glau-
coma. Invest Ophthalmol Vis Sci. 2000;41:764‐774.
 110. Knox DL, Eagle RC Jr, Green WR. Optic nerve hydropic axonal 
degeneration and blocked retrograde axoplasmic transport: histo-
pathologic features in human high‐pressure secondary glaucoma. 
Arch Ophthalmol. 2007;125:347‐353.
 111. Salinas‐Navarro M, Alarcon‐Martinez L, Valiente‐Soriano FJ, et 
al. Ocular hypertension impairs optic nerve axonal transport lead-
ing to progressive retinal ganglion cell degeneration. Exp Eye Res. 
2010;90:168‐183.
 112. Fahy ET, Chrysostomou V, Crowston JG. Mini‐review: impaired 
axonal transport and glaucoma. Curr Eye Res. 2016;41:273‐283.
 113. Ward NJ, Ho KW, Lambert WS, et al. Absence of transient recep-
tor potential vanilloid‐1 accelerates stress‐induced axonopathy in 
the optic projection. J Neurosci. 2014;34:3161‐3170.
 114. Agarwal R, Gupta SK, Agarwal P, et al. Current concepts 
in the pathophysiology of glaucoma. Indian J Ophthalmol. 
2009;57:257‐266.
 115. Flammer J, Haefliger IO, Orgul S, et al. Vascular dysregulation: 
a principal risk factor for glaucomatous damage? J Glaucoma. 
1999;8:212‐219.
 116. Michelson G, Langhans MJ, Harazny J, et al. Visual field defect 
and perfusion of the juxtapapillary retina and the neuroretinal rim 
area in primary open‐angle glaucoma. Graefes Arch Clin Exp. 
1998;236:80‐85.
 117. Chung HS, Harris A, Kagemann L, et al. Peripapillary reti-
nal blood flow in normal tension glaucoma. Br J Ophthalmol. 
1999;83:466‐469.
 118. Gelatt KN, Miyabayashi T, Gelatt‐Nicholson KJ, et al. Progressive 
changes in ophthalmic blood velocities in Beagles with primary 
open angle glaucoma. Vet Ophthalmol. 2003;6:77‐84.
 119. Gelatt‐Nicholson KJ, Gelatt KN, MacKay EO, et al. Comparative 
Doppler imaging of the ophthalmic vasculature in normal Beagles 
and Beagles with inherited primary open‐angle glaucoma. Vet 
Ophthalmol. 1999;2:97‐105.
 120. Brooks DE, Samuelson DA, Gelatt KN. Ultrastructural changes 
in laminar optic nerve capillaries of beagles with primary open‐
angle glaucoma. Am J Vet Res. 1989;50:929‐935.
 121. Mozaffarieh M, Grieshaber MC, Orgul S, et al. The potential value 
of natural antioxidative treatment in glaucoma. Surv Ophthalmol. 
2008;53:479‐505.
 122. Liu Q, Ju WK, Crowston JG, et al. Oxidative stress is an early 
event in hydrostatic pressure induced retinal ganglion cell dam-
age. Invest Ophthalmol Vis Sci. 2007;48:4580‐4589.
 123. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate 
in glaucoma. Exp Eye Res. 2009;88:825‐830.
 124. Bell K, Gramlich OW, Von Thun Und Hohenstein‐Blaul N, et al. 
Does autoimmunity play a part in the pathogenesis of glaucoma? 
Prog Retinal Eye Res. 2013;36:199‐216.
 125. Pumphrey SA, Pizzirani S, Pirie CG, et al. Western blot pat-
terns of serum autoantibodies against optic nerve antigens in 
dogs with goniodysgenesis‐related glaucoma. Am J Vet Res. 
2013;74:621‐628.
 126. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the 
healthy and diseased retina. Prog Retin Eye Res. 2006;25:397‐424.
 127. Son JL, Soto I, Oglesby E, et al. Glaucomatous optic nerve injury 
involves early astrocyte reactivity and late oligodendrocyte loss. 
Glia. 2010;58:780‐789.
740 |   KOMÁROMY et al.
 128. Inman DM, Horner PJ. Reactive nonproliferative gliosis pre-
dominates in a chronic mouse model of glaucoma. Glia. 
2007;55:942‐953.
 129. Neufeld AH, Liu B. Glaucomatous optic neuropathy: when glia 
misbehave. Neuroscientist. 2003;9:485‐495.
 130. Fick CM, Dubielzig RR. Short posterior ciliary artery anatomy 
in normal and acutely glaucomatous dogs. Vet Ophthalmol. 
2016;19:43‐49.
 131. Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of 
memantine treatment for reduction of changes associated with ex-
perimental glaucoma in monkey, I: Functional measures. Invest 
Ophthalmol Vis Sci. 2004;45:2625‐2639.
 132. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety 
of memantine treatment for reduction of changes associated with 
experimental glaucoma in monkey, II: Structural measures. Invest 
Ophthalmol Vis Sci. 2004;45:2640‐2651.
 133. WoldeMussie E, Yoles E, Schwartz M, et al. Neuroprotective 
effect of memantine in different retinal injury models in rats. J 
Glaucoma. 2002;11:474‐480.
 134. Weinreb RN, Liebmann JM, Cioffi GA, et al. Oral memantine 
for the treatment of glaucoma: design and results of 2 random-
ized, placebo‐controlled, phase 3 studies. Ophthalmology. 
2018;125:1874‐1885.
 135. Pease ME, Zack DJ, Berlinicke C, et al. Effect of CNTF on ret-
inal ganglion cell survival in experimental glaucoma. Invest 
Ophthalmol Vis Sci. 2009;50:2194‐2200.
 136. Kallberg ME, Brooks DE, Komaromy AM, et al. The effect of an 
L‐type calcium channel blocker on the hemodynamics of orbital 
arteries in dogs. Vet Ophthalmol. 2003;6:141‐146.
 137. Jutley G, Luk SM, Dehabadi MH, et al. Management of glau-
coma as a neurodegenerative disease. Neurodegener Dis Manag. 
2017;7:157‐172.
 138. Becker S, Eastlake K, Jayaram H, et al. Allogeneic transplantation 
of Müller‐derived retinal ganglion cells improves retinal function 
in a feline model of ganglion cell depletion. Stem Cells Transl 
Med. 2016;5:192‐205.
 139. Benowitz LI, He Z, Goldberg JL. Reaching the brain: advances in 
optic nerve regeneration. Exp Neurol. 2017;287:365‐373.
 140. Laha B, Stafford BK, Huberman AD. Regenerating optic path-
ways from the eye to the brain. Science. 2017;356:1031‐1034.
 141. Goldberg JL, Guido W, AGI Workshop Participants. Report on the 
National Eye Institute Audacious Goals Initiative: Regenerating 
the optic nerve. Invest Ophthalmol Vis Sci. 2016;57:1271‐1275.
 142. Tanaka T, Yokoi T, Tamalu F, et al. Generation of retinal ganglion 
cells with functional axons from human induced pluripotent stem 
cells. Sci Rep. 2015;5:8344.
 143. Miller PE. The glaucomas. In: Maggs DJ, Miller PE, Ofri R eds. 
Slatter's Fundamentals of Veterinary Ophthalmology. 5th edition. 
St. Louis, MO: Elsevier. 2013; 258.
How to cite this article: Komáromy AM, Bras D, 
Esson DW, et al. The future of canine glaucoma 
therapy. Vet Ophthalmol. 2019;22:726–740. https ://doi.
org/10.1111/vop.12678 
